The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin has the Capacity to Repair β-Cell Dysfunction and Insulin Resistance

2014 ◽  
Vol 46 (11) ◽  
pp. 814-818 ◽  
Author(s):  
A. Horie ◽  
Y. Tokuyama ◽  
T. Ishizuka ◽  
Y. Suzuki ◽  
K. Marumo ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Dipeptidyl Peptidase ◽  
Β Cell ◽  
Dipeptidyl Peptidase 4 ◽  
Cell Dysfunction ◽  
Dipeptidyl Peptidase 4 Inhibitor

scholarly journals Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Wenbin Zheng ◽  
Jing Zhou ◽  
Shasha Song ◽  
Wen Kong ◽  
Wenfang Xia ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hepatic Steatosis ◽  
Inflammatory Responses ◽  
Body Weight Gain ◽  
Biological Activities ◽  
Dipeptidyl Peptidase ◽  
Hepatic Insulin Resistance ◽  
Dipeptidyl Peptidase 4 ◽  
Obesity And Diabetes ◽  
Dipeptidyl Peptidase 4 Inhibitor

Obesity and type 2 diabetes are the most common metabolic diseases globally. They are associated with inflammation, oxidative stress, autophagy, and insulin resistance. Sitagliptin, a dipeptidyl-peptidase 4 inhibitor, has been reported to show multiple biological activities beyond the antidiabetic property. This study was aimed at investigating the effect of sitagliptin on hepatic steatosis, insulin resistance, inflammation, and autophagy and exploring the underlying molecular mechanism. In the current study, ob/ob mice, a mouse model of genetic obesity and diabetes, were administered via gavage with sitagliptin 50 mg/kg daily for 4 weeks. Changes in glycolipid metabolism, inflammatory responses, and autophagy in the liver were evaluated. Body weight gain, lipid metabolic disorder, and hepatic steatosis as well as systemic and hepatic insulin sensitivity in ob/ob mice were significantly attenuated after sitagliptin treatment. Furthermore, sitagliptin decreased inflammatory responses by regulating macrophage M1/M2 polarization and inhibiting the activities of NF-κB and JNK. Moreover, sitagliptin increased the levels of phosphorylation of AMPK and decreased those of mTOR. This study indicates that sitagliptin significantly ameliorates the development of hepatic steatosis and insulin resistance in ob/ob mice by inhibiting inflammatory responses and activating autophagy via AMPK/mTOR signaling pathway.

Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance

2018 ◽  
Vol 85 ◽  
pp. 148-153 ◽  
Author(s):  
Jitjiroj Ittichaicharoen ◽  
Nattayaporn Apaijai ◽  
Pongpan Tanajak ◽  
Piangkwan Sa-nguanmoo ◽  
Nipon Chattipakorn ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Salivary Glands ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor

Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus

2011 ◽  
Vol 7 (5) ◽  
pp. 325-335 ◽  
Author(s):  
Somsuvra B. Ghatak ◽  
Devang S. Patel ◽  
Neeraj Shanker ◽  
Ambrish Srivastava ◽  
Shrikalp S. Deshpande ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Dipeptidyl Peptidase ◽  
Type Ii ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document